StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

Analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued to investors on Wednesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Up 4.7 %

Shares of EGRX stock opened at $4.43 on Wednesday. Eagle Pharmaceuticals has a 12-month low of $3.21 and a 12-month high of $16.21. The firm has a fifty day moving average of $4.81 and a 200-day moving average of $4.76. The company has a market capitalization of $57.53 million, a price-to-earnings ratio of 3.75 and a beta of 0.53.

Institutional Trading of Eagle Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of EGRX. Headlands Technologies LLC grew its holdings in shares of Eagle Pharmaceuticals by 75.7% during the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 2,861 shares in the last quarter. Mackenzie Financial Corp bought a new stake in shares of Eagle Pharmaceuticals in the second quarter worth $60,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Eagle Pharmaceuticals during the second quarter worth $65,000. Fidelis Capital Partners LLC bought a new position in Eagle Pharmaceuticals in the second quarter valued at $71,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Eagle Pharmaceuticals in the 2nd quarter valued at $76,000. Institutional investors and hedge funds own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.